ReposiTrak Earnings Calls
| Release date | May 14, 2026 |
| EPS estimate | $0.0930 |
| EPS actual | $0.110 |
| EPS Surprise | 18.28% |
| Revenue estimate | 5.9B |
| Revenue actual | 5.883B |
| Revenue Surprise | -0.285% |
| Release date | Feb 17, 2026 |
| EPS estimate | $0.0900 |
| EPS actual | $0.0900 |
| Revenue estimate | 5.765M |
| Revenue actual | 5.857M |
| Revenue Surprise | 1.59% |
| Release date | Nov 13, 2025 |
| EPS estimate | $0.0900 |
| EPS actual | $0.0900 |
| Revenue estimate | 5.985M |
| Revenue actual | 5.971M |
| Revenue Surprise | -0.226% |
| Release date | Sep 29, 2025 |
| EPS estimate | $0.0900 |
| EPS actual | $0.0900 |
| Revenue estimate | 6.25M |
| Revenue actual | 5.76M |
| Revenue Surprise | -7.84% |
Last 4 Quarters for ReposiTrak
Below you can see how TRAK performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Sep 29, 2025 |
| Price on release | $16.56 |
| EPS estimate | $0.0900 |
| EPS actual | $0.0900 |
| Date | Price |
|---|---|
| Sep 23, 2025 | $17.32 |
| Sep 24, 2025 | $17.52 |
| Sep 25, 2025 | $17.02 |
| Sep 26, 2025 | $16.93 |
| Sep 29, 2025 | $16.56 |
| Sep 30, 2025 | $14.82 |
| Oct 01, 2025 | $15.70 |
| Oct 02, 2025 | $15.46 |
| Oct 03, 2025 | $14.92 |
| 4 days before | -4.39% |
| 4 days after | -9.90% |
| On release day | -10.51% |
| Change in period | -13.86% |
| Release date | Nov 13, 2025 |
| Price on release | $15.00 |
| EPS estimate | $0.0900 |
| EPS actual | $0.0900 |
| Date | Price |
|---|---|
| Nov 07, 2025 | $15.02 |
| Nov 10, 2025 | $15.00 |
| Nov 11, 2025 | $15.01 |
| Nov 12, 2025 | $15.05 |
| Nov 13, 2025 | $15.00 |
| Nov 14, 2025 | $15.04 |
| Nov 17, 2025 | $14.55 |
| Nov 18, 2025 | $14.10 |
| Nov 19, 2025 | $13.95 |
| 4 days before | -0.133% |
| 4 days after | -7.00% |
| On release day | 0.267% |
| Change in period | -7.12% |
| Release date | Feb 17, 2026 |
| Price on release | $10.09 |
| EPS estimate | $0.0900 |
| EPS actual | $0.0900 |
| Date | Price |
|---|---|
| Feb 10, 2026 | $10.63 |
| Feb 11, 2026 | $10.32 |
| Feb 12, 2026 | $10.27 |
| Feb 13, 2026 | $10.29 |
| Feb 17, 2026 | $10.09 |
| Feb 18, 2026 | $9.20 |
| Feb 19, 2026 | $8.99 |
| Feb 20, 2026 | $8.76 |
| Feb 23, 2026 | $8.38 |
| 4 days before | -5.08% |
| 4 days after | -16.95% |
| On release day | -8.82% |
| Change in period | -21.17% |
| Release date | May 14, 2026 |
| Price on release | $9.10 |
| EPS estimate | $0.0930 |
| EPS actual | $0.110 |
| EPS surprise | 18.28% |
| Date | Price |
|---|---|
| May 08, 2026 | $10.23 |
| May 11, 2026 | $9.81 |
| May 12, 2026 | $9.34 |
| May 13, 2026 | $9.02 |
| May 14, 2026 | $9.10 |
| May 15, 2026 | $9.70 |
| May 18, 2026 | $9.94 |
| May 19, 2026 | $9.85 |
| May 20, 2026 | $9.73 |
| 4 days before | -11.05% |
| 4 days after | 6.92% |
| On release day | 6.59% |
| Change in period | -4.89% |
ReposiTrak Earnings Call Transcript Summary of Q1 2026
ReposiTrak reported a solid start to Fiscal 2026 with Q1 revenue up 10% to $6.0M, operating income up 28% to $1.9M and GAAP net income of $1.8M (EPS $0.10 basic, $0.09 diluted). The company is maintaining its strategy of 10–20% ARR growth, higher profitability, strong cash generation (cash on hand $28.8M, no bank debt) and shareholder returns (targeting returning 50% of annual free cash flow via dividends, share repurchases and preferred redemptions). Operating expenses rose modestly (total op ex +3%, SG&A +6%) due to investments in RTN (including onboarding Wizards), cybersecurity and database licenses. Management highlighted the end of historical NOL tax benefits—effective tax rate is expected to rise above the prior ~4–6% range—and said they are pursuing tax credits to mitigate the impact. They announced a multi-year platform modernization (reallocating existing CapEx and developer resources) to embed more AI and automation, drive productivity, expand automation-driven error detection/correction capabilities (a core differentiator given ~70% initial data error rates), and enable scalable cross-selling across their single-platform product suite. Capital allocation progress: $6.1M of preferred redeemed to date (remaining ~$2.8M targeted to be redeemed by Dec 2026 at current pace), $150k of common repurchases in the quarter with ~$7.8M remaining buyback authorization, and three dividend increases since Dec 2023. Management reiterated confidence in doubling company size over the coming years driven by traceability leadership, cross-selling, high gross margins and continued cash generation.
Sign In
Buy TRAK